Merck Loses Bid To Toss 24 Fosamax Cases

Law360, New York (September 9, 2009, 7:06 PM EDT) -- A judge in charge of multidistrict litigation over Merck & Co. Inc.'s Fosamax has denied the drugmaker's motion to dismiss 24 cases that alleged the osteoporosis drug could cause jaw damage in patients who took the drug for less than three years.

Judge John Keenan of the U.S. District Court for the Southern District of New York on Wednesday rejected Merck's bid for summary judgment and ruled that two of three expert witnesses for the plaintiffs could testify that Fosamax could cause the bone degenerative disease...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.